NextCure  Inc

NASDAQ: NXTC
$1.44
-$0.09 (-5.9%)
Closing price April 24, 2024
NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other diseases related to the immune system by restoring normal immune function. The company is headquartered in Beltsville, Maryland.

Top Analyst Upgrades and Downgrades: Autodesk, Costco, Interactive Brokers, SBA Communications, Western Digital, Zscaler and More
Friday's top analyst upgrades and downgrades included Autodesk, Costco, Gap, Interactive Brokers, SBA Communications, Smith & Wesson, Western Digital and Zscaler.
Lee Jackson
Published:
Last Updated:

Why Investors Are Pumping the Brakes on NextCure's Cancer Treatment
NextCure updated clinical results from its early stage cancer study at the Society for Immunotherapy of Cancer annual meeting. As a result, NextCure shares were crushed on Monday.
Chris Lange
Published:

Is NextCure the Next Big Cancer Biotech Every Investor Missed?
NextCure appears to be one of those companies that has flown under the radar of the investing community since its initial public offering in 2019.
Jon C. Ogg
Published: